ATS Corporation (ATS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented a strong backlog, positive integration of acquisitions, and favorable market conditions for automation. Management's optimistic guidance on margin improvements and leverage targets, along with strategic diversification efforts, indicate a positive outlook. The Q&A reinforced this sentiment, revealing minimal negative impact from external pressures and ongoing M&A activity. The market cap suggests a moderate reaction, leading to a 'Positive' stock price prediction over the next two weeks.
Key Financial Performance
Q1 revenues $737 million, up 6% from Q1 last year. Reasons for change include solid contributions from recent acquisitions and a 3.2% benefit from foreign exchange translation. However, organic revenue growth was negative 1.2% due to lower transportation revenues, partially offset by growth in life sciences, consumer products, and food and beverage.
Order bookings $693 million, down 15% compared to Q1 last year. Reasons for decline include a lower expected run rate in transportation order bookings and the absence of several larger enterprise order bookings in life sciences that were present in Q1 last year.
Order backlog Approximately $2.1 billion, with Life Sciences contributing $1.2 billion and Food and Beverage contributing $229 million (up 6% compared to Q1 last year). Reasons for growth in Food and Beverage include investment in primary processing solutions and aftermarket services.
Adjusted earnings from operations $78.6 million or 10.7% of revenues, in line with expectations and representing a 40 basis point sequential improvement from Q4. Gross margin for Q1 was 29.8%, consistent with Q1 last year.
SG&A expenses $136.4 million, a $20 million increase over the prior year. Reasons for increase include incremental SG&A from acquired companies, foreign exchange translation, and employee costs.
Earnings per share (EPS) $0.41 on an adjusted basis.
Cash flows from operating activities $156 million in Q1, supported by the EV settlement payment received during the quarter.
CapEx and intangible assets investment $16.3 million in Q1, aimed at driving innovation and capability.
Net debt to adjusted EBITDA ratio 3.6x on a pro forma basis in Q1, improved from Q4 due to the EV settlement payment used to reduce credit facility debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Life Sciences: Order backlog at quarter end was $1.2 billion. Wins in submarkets like auto-injectors, radiopharma, and blood glucose monitoring wearables. Comecer opened a new site in Indianapolis to support radiopharma customers.
Food and Beverage: Backlog of $229 million, up 6% from Q1 last year. Focus on primary processing solutions and aftermarket service. Growth strategy includes secondary processing, packaging, and services supported by Paxiom.
Energy: Advanced deployment of the Multiplex system for nuclear reactor decommissioning and waste handling. Opportunities in CANDU refurbishment and small modular reactor programs.
Digital Innovation: Launched a new virtual reality training platform for customers, leveraging a recent acquisition.
Nuclear Industry: Benefiting from renewed investment and favorable government policy. Opportunities in both large-scale new builds and small modular reactor programs.
Consumer Products: Stable funnel with niche opportunities in warehouse automation and packaging.
Transportation: Stable funnel but lower EV end market demand.
Revenue Growth: Q1 revenues were $737 million, up 6% from last year. Order backlog at $2.1 billion provides solid revenue visibility.
Operational Efficiencies: Focus on Kaizens, workshops, and problem-solving events to improve value drivers. ABM tools critical for margin expansion.
Supply Chain: Strategic sourcing approach to protect margins and minimize disruption. Majority of exports from Canada to the U.S. covered under USMCA.
M&A Strategy: Focus on cultivating strategic opportunities aligned with long-term growth ambitions. Near-term focus on returning leverage to target range and realizing synergies from recent acquisitions.
Services Portfolio: Designed to strengthen customer relationships and drive recurring revenue. Includes digital solutions like the Connected Care Hub.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership Transition: The company is undergoing a leadership transition with the CEO stepping down. While the interim CEO and senior leadership team are experienced, such transitions can create uncertainty and potential disruptions in strategic execution.
Order Bookings Decline: Order bookings were down 15% compared to Q1 last year, primarily due to lower transportation order bookings and variability in life sciences enterprise orders. This decline could impact future revenue growth.
Transportation Market Weakness: Lower demand in the EV end market has negatively impacted transportation revenues and order bookings, contributing to a decline in organic revenue growth.
Lab Research Capital Spending: Some customers in the lab research space are taking a more measured approach to capital spending due to changes in U.S. government funding, which could affect future revenue in this segment.
Tariff and Cross-Border Dynamics: The company is closely monitoring cross-border tariffs and trade dynamics, which could pose risks to cost structures and supply chain efficiency.
Supply Chain Risks: While the company has a strategic sourcing approach, supply chain disruptions remain a potential risk, especially in a volatile global environment.
Restructuring Costs: The company incurred $2.5 million in restructuring costs in Q1, which could impact short-term profitability.
Leverage and Debt Levels: Net debt to adjusted EBITDA ratio is at 3.6x, above the target range of 2-3x. High leverage could limit financial flexibility and increase risk in a rising interest rate environment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Order Backlog and Revenue Visibility: Order backlog ended the quarter at approximately $2.1 billion, providing solid revenue visibility and a strong foundation for profitable growth. Q2 revenues are expected to be in the range of $700 million to $740 million. Full-year revenue growth outlook remains unchanged.
Life Sciences Segment: Order backlog at quarter end was $1.2 billion, with strong opportunities in submarkets like auto-injectors, radiopharma, and blood glucose monitoring wearables. The outlook for Life Sciences remains strong despite some measured capital spending in the lab research space.
Food and Beverage Segment: Backlog increased to $229 million, up 6% compared to Q1 last year. Continued investment in primary processing solutions and growth strategy for secondary processing, packaging, and services are expected to drive future performance.
Energy Segment: The nuclear industry is benefiting from renewed investment and favorable government policy. Near-term growth is driven by CANDU refurbishment activity, while long-term opportunities include large-scale new builds and small modular reactor programs.
Transportation Segment: Order bookings in transportation are lower due to relatively lower EV end market demand. However, the segment remains stable with no significant changes expected in the near term.
Services and Digital Solutions: Advancing digital solutions, including the Connected Care Hub, to enhance system utilization and mitigate risk. The services portfolio is designed to drive recurring revenue and strengthen customer relationships over the equipment lifecycle.
Operating Margin and Efficiency: Operating margin improvement is expected throughout fiscal 2026, supported by ABM tools and strategic sourcing to protect margins and minimize supply chain disruptions.
Capital Expenditures and Leverage: Invested $16.3 million in CapEx and intangible assets in Q1 to drive innovation and capability. Committed to reducing leverage to a target range of 2 to 3x net debt to adjusted EBITDA.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: The NCIB (Normal Course Issuer Bid) program was mentioned as an opportunistic component of the company's overall capital deployment strategy. The company was active on its share buyback program during Q1.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the adjusted demand environment and the outlook for the rest of the year?
A:Management highlighted a strong trailing 12-month book-to-bill ratio of 1.17, indicating alignment with growth targets. They noted healthy funnels and engaging customer conversations across key markets like life sciences, energy, food, transportation, and consumer products. Specific growth areas include GLP-1 drugs, radiopharma, nuclear energy, and pharmacy automation. Orders excluding transportation were up over 10% year-over-year in the first half of the calendar year.
Q:What drove the material uptick in the energy business backlog this quarter?
A:The growth in the energy business was primarily driven by nuclear refurbishment activities, especially around CANDU reactors. Management also mentioned smaller contributions from SMR (Small Modular Reactor) development and fuel handling, which are seen as future opportunities.
Q:Can you provide an update on the integration process and cross-selling opportunities for ABM, Avidity, and Heidolph?
A:Management reported strong progress in integration, with ABM deployments and cost synergies meeting expectations. Cross-selling opportunities are growing, particularly with ATS life sciences systems working with BioDot, Avidity, and Heidolph. Heidolph has been a welcome addition, enhancing the lab space offerings.
Q:What is the impact of U.S. research funding pressures on the life sciences business?
A:The impact is minimal, representing a low single-digit percentage of the life sciences business. Management noted no material effect on the overall business.
Q:How should we think about the margin progression in the short and medium term?
A:Management expects medium-term margin expansion driven by gross margin improvements through supply chain and labor productivity initiatives. Short-term margins may vary due to project portfolio execution, but the overall outlook for the year remains positive.
Q:Is there anything in the project pipeline restraining short-term margin progress?
A:No, there is nothing unusual or restraining short-term margin progress.
Q:What is the outlook for M&A activity given the leadership transition?
A:Management stated that M&A activity and cultivation are continuing as planned. The focus remains on deleveraging to a 2x to 3x range, but smaller tuck-in acquisitions are still possible in the short term.
Q:Are U.S. CapEx announcements from life sciences customers translating to increased activity for ATS?
A:While there are discussions and some decisions to build capacity in the U.S., these have not yet translated into significant orders for ATS. However, the environment is generally favorable for automation.
Q:Was the EV settlement fully received this quarter, and were there any tax implications?
A:The EV settlement was fully received this quarter with no tax impact on the cash inflow.
Q:When does management expect to achieve the 2x to 3x leverage target?
A:Management expects to achieve the leverage target by the end of the fiscal year, primarily through working capital improvements.
Q:Can you provide insights into the food and beverage CapEx outlook in North America?
A:Management reported stability and additional opportunities in the food and beverage sector, supported by investments in technology and innovation through businesses like Paxiom, CFT, and Raytec.
Q:Is there anything in the portfolio considered non-core?
A:No, management does not currently consider any part of the portfolio as non-core but continues to evaluate the portfolio annually.
Q:What capabilities does ATS have in lab automation, and how does it align with recent White House initiatives?
A:ATS has capabilities in lab automation through businesses like Climet, Avidity, SP, and Heidolph. These businesses support various aspects of lab automation and consumables, but the overall impact on ATS is relatively small.
Q:What is the multiplex system, and what applications does it serve?
A:The multiplex system is used in nuclear decommissioning, enabling more efficient and space-conscious processes. It supports traditional nuclear reactors and has won awards with a growing funnel of opportunities.
Q:How diversified is the life sciences business outside of GLP-1 applications?
A:The majority of the auto-injector business is tied to GLP-1, but it is diversified across 10 active customers. Emerging applications include cardiovascular health and neurological disorders.
Q:What caused the slower pace of bookings in the life sciences sector this quarter?
A:The slower pace was due to the timing of larger programs, particularly in wearables and auto-injectors, which showed normal variability.
Q:What is the timeline for bringing working capital back to the 15% range, and where is it currently elevated?
A:Management aims to achieve the 15% target by the end of the fiscal year. Working capital is currently elevated in inventory terms for product-based businesses and payment terms in the custom automation business.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the short-term margin progression, stating only that there would be variability and no linear ramp. Additionally, they did not elaborate on the specific timing or scale of M&A opportunities, citing leverage constraints as a governing factor.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABM award
AI advancement
ATS Automation
CEO
Corporate Participant
Division Patrick
Hider
Inc Research
Life Sciences
Order booking
Relations Associate
Research Division
customer program
customer relationship
end market
event
foundation
government
investment
life cycle
line expectation
partner
portfolio
reality
result today
service addition
support
system
transformation
transition ATS
waste handling
workshop
ATS Transcript
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
Positive5-28
The earnings call summary and Q&A highlight strong backlogs across key sectors, positive revenue guidance, and strategic investments in growth areas. Despite some restructuring costs, the company is focused on margin expansion and capital efficiency. The Q&A reveals confidence in future growth, particularly in Life Sciences and nuclear segments, and potential M&A activities. The strategic plan and strong working capital management further support a positive outlook. Given the market cap, these factors suggest a stock price movement in the 2% to 8% range over the next two weeks.
ATS Corporation (ATS:CA) Q3 2026 Earnings Call Transcript
Unknown2-4
The earnings call presents a mixed picture. While there is optimism about growth in Life Sciences and nuclear segments, and a strong order backlog, the decrease in gross margin and increased SG&A expenses are concerns. The Q&A reveals cautious optimism but lacks specific guidance, which may cause uncertainty. Given the market cap of $3.18 billion, the stock is likely to have a muted reaction, resulting in a neutral sentiment.
ATS Corporation (ATS:CA) Q2 2026 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate strong financial performance, with a solid order backlog and promising growth in segments like Life Sciences and Energy. Despite some uncertainties, management provided optimistic guidance, focusing on margin expansion and strategic initiatives. The stock is likely to experience a positive movement, considering the company's market cap and the absence of significant negative factors.
ATS Corporation (ATS) Q1 2026 Earnings Call Transcript
Positive8-7
The earnings call presented a strong backlog, positive integration of acquisitions, and favorable market conditions for automation. Management's optimistic guidance on margin improvements and leverage targets, along with strategic diversification efforts, indicate a positive outlook. The Q&A reinforced this sentiment, revealing minimal negative impact from external pressures and ongoing M&A activity. The market cap suggests a moderate reaction, leading to a 'Positive' stock price prediction over the next two weeks.
ATS Slides
ATS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
